A randomized phase III study of continuous maintenance Bevacizumab with or without Pemetrexed after induction therapy of Carboplatin, Pemetrexed, and Bevacizumab in patients with advanced non-squamous non-small-cell lung cancer whose EGFR mutation status is not active (other than Exon 19 deletion or Exon 21 point mutation) or is not known

Trial Profile

A randomized phase III study of continuous maintenance Bevacizumab with or without Pemetrexed after induction therapy of Carboplatin, Pemetrexed, and Bevacizumab in patients with advanced non-squamous non-small-cell lung cancer whose EGFR mutation status is not active (other than Exon 19 deletion or Exon 21 point mutation) or is not known

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2015

At a glance

  • Drugs Pemetrexed (Primary) ; Bevacizumab; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms COMPASS
  • Most Recent Events

    • 09 Sep 2015 Status changed from recruiting to active, no longer recruiting according to University Hospital Medical Information Network - Japan.
    • 29 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top